Antibodies News and Research

RSS

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.

4 Oct 2020

New multiplexed test with a low-cost sensor may enable at-home COVID diagnosis

One feature of the COVID-19 virus that makes it so difficult to contain is that it can be easily spread to others by a person who has yet to show any signs of infection.

1 Oct 2020

Researchers receive NCI grant to study role of collagens in breast cancer

An MUSC Hollings Cancer Center researcher received a $3 million grant from the National Cancer Institute to study how patterns of collagens can serve as biomarkers of breast cancer risk and potentially reveal clues to what might be driving health disparities.

1 Oct 2020

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

30 Sep 2020

Researchers identify the target structures for T-cell response against SARS-CoV-2

Our immune system can efficiently fend off viral diseases. Two types of immune cells play an important role in this process: The T-cells, which firstly can directly destroy virus-infected cells and secondly enable the formation of efficient, virus-neutralizing antibodies by B-cells.

30 Sep 2020

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Researchers in the United States and Japan have conducted a study showing a common mutation in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVD-19) - enhances the infectivity, replication, and early transmission of the virus.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

Danish vs. Swedish data shows social interaction major risk factor for SARS-CoV-2 infection

A new study published on the preprint server medRxiv* in September 2020 compares the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Danish and Swedish healthcare workers, to conclude that “social interaction is one of the biggest risk factors for getting infected with SARS-CoV-2.”

30 Sep 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

29 Sep 2020

Common cold in the past may provide some protection from COVID-19

Seasonal colds are by all accounts no fun, but new research suggests the colds you've had in the past may provide some protection from COVID-19.

29 Sep 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Now, a recent study published on the preprint server medRxiv* in September 2020 shows the achievement of herd immunity for SARS-CoV-2 infection by at least some expatriate worker communities in Qatar.

29 Sep 2020

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Antibody-based immunotherapy is one of treatment options for cancer immunotherapy by modulating our immune system with therapeutic antibodies.

29 Sep 2020

Corralling the facts on herd immunity

For a term that's at least 100 years old, "herd immunity" has gained new life in 2020.

29 Sep 2020

Computer model unravels mystery behind severe inflammation in people with COVID-19

A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation?

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

A recent study by French researchers has demonstrated that experimental exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) is capable of inducing mild infection in hamsters and ferrets within 7 – 10 days of exposure. However, the infection completely resolves within 14 days. The study is currently available on the bioRxiv preprint server.

28 Sep 2020

Antibodies News and Research

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

New multiplexed test with a low-cost sensor may enable at-home COVID diagnosis

Researchers receive NCI grant to study role of collagens in breast cancer

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

Researchers identify the target structures for T-cell response against SARS-CoV-2

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Newly developed fusion protein could improve COVID-19 research

Danish vs. Swedish data shows social interaction major risk factor for SARS-CoV-2 infection

Researchers identify a new method to produce miniaturized antibodies

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Common cold in the past may provide some protection from COVID-19

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Corralling the facts on herd immunity

Computer model unravels mystery behind severe inflammation in people with COVID-19

SARS-CoV-2 re-infection is real but rare: Case study

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News